Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma

M. Kupczyk (Lodz, Poland), P. Majak (Lodz, Poland), P. Kuna (Lodz, Poland), B. Asankowicz-Bargiel (Ostrow Wlkp., Poland), E. Baranska (Chodziez, Poland), R. Dobek (Wolow, Poland), S. Garbicz (Slupsk, Poland), J. Jerzynska (Lodz, Poland), A. Latos (Kielce, Poland), W. Machowiak (Koscian, Poland), B. Majorek-Olechowska (Tarnow, Poland), A. Olech-Cudzik (Ostrowiec Sw., Poland), I. Poziomkowska-Gesicka (Szczecin, Poland), M. Rulewicz-Warniello (Ketrzyn, Poland), A. Swiderska (Wielun, Poland), M. Tarnowski (Warsaw, Poland), P. Kopyto (Lodz, Poland)

Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Session: Asthma inhalers: devices and adherence studies
Session type: E-poster session
Number: 3182
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Kupczyk (Lodz, Poland), P. Majak (Lodz, Poland), P. Kuna (Lodz, Poland), B. Asankowicz-Bargiel (Ostrow Wlkp., Poland), E. Baranska (Chodziez, Poland), R. Dobek (Wolow, Poland), S. Garbicz (Slupsk, Poland), J. Jerzynska (Lodz, Poland), A. Latos (Kielce, Poland), W. Machowiak (Koscian, Poland), B. Majorek-Olechowska (Tarnow, Poland), A. Olech-Cudzik (Ostrowiec Sw., Poland), I. Poziomkowska-Gesicka (Szczecin, Poland), M. Rulewicz-Warniello (Ketrzyn, Poland), A. Swiderska (Wielun, Poland), M. Tarnowski (Warsaw, Poland), P. Kopyto (Lodz, Poland). Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma. 3182

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 429s
Year: 2002

Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005

The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus™ and MDI in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Efficacy of salmeterol/fluticasone pMDI versus DPI in patients with asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006

Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Efficacy and safety of fluticasone propionate/salmeterol DISKUS and fluticasone propionate DISKUS and HFA in children
Source: Eur Respir J 2005; 26: Suppl. 49, 161s
Year: 2005

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014



Does Clickhaler match the Turbuhaler for efficacy of inhaled budesonide?
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
Source: ERJ Open Res, 6 (2) 00187-2019; 10.1183/23120541.00187-2019
Year: 2020



Same minimal effective dose of budesonide Turbuhaler® and fluticasone Diskus®/Accuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013